ONCY
Oncolytics BiotechONCY
ONCY
About: Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
Employees: 28
0
Funds holding %
of 7,429 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
140% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 5
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
53% more capital invested
Capital invested by funds: $750K [Q1] → $1.15M (+$399K) [Q2]
10% more funds holding
Funds holding: 50 [Q1] → 55 (+5) [Q2]
0% more ownership
Funds ownership: 1.58% [Q1] → 1.58% (+0%) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$7
608%
upside
Avg. target
$7
608%
upside
High target
$7
608%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Lake Street Chad Messer | 608%upside $7 | Buy Initiated | 13 Aug 2025 |
Financial journalist opinion
Based on 5 articles about ONCY published over the past 30 days
Neutral
PRNewsWire
2 weeks ago
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
SAN DIEGO , Aug. 11, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Corporation" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Friday, August 8, 2025. A total of 37.42% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.
Neutral
PRNewsWire
2 weeks ago
Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study New members of the management team bring expertise in progressing clinical programs and executing successful biotech transactions Translational data further elucidate pelareorep's mechanism of action and ability to prime the tumor microenvironment for treatment Commitment to limiting dilution evidenced by termination of At-the-Market and Equity Line of Credit facilities SAN DIEGO , Aug. 8, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today reported financial results and recent highlights for the second quarter of 2025. All dollar amounts are expressed in Canadian currency unless otherwise noted.
Neutral
PRNewsWire
2 weeks ago
Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange
SAN DIEGO , Aug. 8, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced that the common shares in the capital of the Company (the "Shares") will be voluntarily delisted from the Toronto Stock Exchange ("TSX") at the close of markets on August 22, 2025, pursuant to the Company's application for voluntary delisting and the satisfaction of the conditions to delist from the TSX. The delisting from the TSX will not affect the Company's listing on the Nasdaq.
Neutral
PRNewsWire
3 weeks ago
Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results
The management team will provide a brief corporate update after the formal portion of the shareholder meeting SAN DIEGO and CALGARY, AB , Aug. 5, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced that its upcoming 2025 Annual General Meeting (the "Meeting") will be held virtually at 10:00 a.m. Eastern Time (ET) on Friday, August 8, 2025, as a virtual-only shareholder meeting.
Neutral
PRNewsWire
4 weeks ago
Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End
Clear regulatory path and strong survival data in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) support accelerated strategy to drive shareholder value and partnership opportunities SAN DIEGO and CALGARY, AB , July 29, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced it has initiated regulatory discussions with the U.S. Food and Drug Administration (FDA) for a potential registration-enabled pivotal study in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). Assuming discussions with the FDA go as expected, the Company expects to commence study start-up activities before the end of 2025.
Neutral
PRNewsWire
1 month ago
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
SAN DIEGO and CALGARY, AB , July 23, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, hosted a key opinion leader (KOL) webinar featuring leading physicians in the fields of oncology and immunotherapy discussing pelareorep's robust clinical data and how it fits in the evolving treatment landscape for pancreatic and gastrointestinal (GI) cancers. The KOLs provided individual presentations and then participated in a roundtable Q&A discussion.
Neutral
PRNewsWire
1 month ago
Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
SAN DIEGO and CALGARY, AB , July 22, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a leading clinical-stage company specializing in immunotherapy for oncology, received a formal letter (the "Compliance Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated July 22, 2025 informing the Company that it has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). The Company is now in compliance with all Nasdaq listing standards, and its common shares will continue to trade on the Nasdaq Capital Market under the ticker "ONCY.
Neutral
PRNewsWire
1 month ago
Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types
Integrated biomarker analyses confirm viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes after pelareorep treatment Cross-study data show pelareorep increases PD-L1 expression and boosts cytotoxic T-cell activity, priming resistant tumors for checkpoint inhibitors Results reinforce pelareorep's ability to turn cold tumors hot, paving the way for registration-enabling trials SAN DIEGO and CALGARY, AB , July 16, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, summarized its biomarker and translational data for pelareorep, the Company's systemically delivered oncolytic virus. The data support pelareorep's mechanism of action and further strengthen the unique biological rationale and therapeutic potential for pelareorep as a platform immunotherapeutic.
Neutral
PRNewsWire
1 month ago
Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers
KOL webinar to take place on July 22, 2025, at 1:00 p.m. ET SAN DIEGO and CALGARY, AB , July 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, announced that it will host a key opinion leader (KOL) webinar to discuss pelareorep in metastatic pancreatic ductal adenocarcinoma (mPDAC) and other gastrointestinal cancers.
Neutral
PRNewsWire
1 month ago
Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies
Comparison with multiple landmark first-line metastatic pancreatic ductal adenocarcinoma studies substantiates strong two-year survival benefit of 21.9% vs. 9.2% historical benchmark Consistent survival benefit compared to standard-of-care chemotherapy in randomized studies in the large HR+/HER2- metastatic breast cancer indication Data from over 1,100 patients across tumor types reveals a favorable, well-understood safety profile SAN DIEGO and CALGARY, AB , July 8, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced a strategic update highlighting its compelling clinical data from two tumor types and outlining a sharpened focus on advancing pelareorep, the Company's intravenously delivered oncolytic virus immunotherapy, into registration-enabling studies.
Charts implemented using Lightweight Charts™